iBio, Inc is a biotechnology company. The Company focuses on commercializing its platform technologies, iBioLaunch and iBioModulator, and developing select product candidates based upon these platforms. iBioLaunch is a transformative platform technology for the development and production of biologics using transient gene expression in hydroponically grown, unmodified green plants.
SAN DIEGO, Oct. 16, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has established a collaboration with iBio, Inc. (NYSE AMERICAN: IBIO) to support potential large-scale production of the Aethlon Hemopurifier®. iBio is a leading developer of plant-based biopharmaceuticals.